Spermidine Mai Yaki da Tsufa na da Tasiri Mai Mummuna a Kan Kwayoyin T na Tsofaffi
Spermidine ana ɗaukarta a matsayin polyamine mai yaki da tsufa, amma wani sabon bincike a kan ƙwayoyin linzamin da aka samo daga farar jiki ya nuna cewa tana iya raunana wasu ƙwayoyin garkuwar jiki masu tsufa. A ƙwayoyin CD49d‑ CD8+ masu kama da senescence, spermidine ta rage aikin mitochondria, ta ƙare ajin antioxidants, kuma ta jawo fashewar mitochondria, yayin da ƙwayoyin CD49d+ ba su nuna wani tasiri ba. Wannan bincike na pre‑clinical ne, ba na ɗan adam ba, kuma yana kalubalantar ra'ayin cewa spermidine na taimaka wa kowace ƙwaya da ke tsufa.
NR Ya Rage Shekarar Epigenetic a Tsokar Ciki; HIIT Ya Haifar da Sauran Tasiri
NR da HIIT ana yawan ɗauka a matsayin dabarun da ke riƙe da tsokar cikin yanayi na ƙuruciya. Sabuwar takardar da aka buga a mujallar *Aging Cell* ta nuna cewa wadannan hanyoyi suna sauya agogon epigenetic na tsoka, amma a bangarori daban‑daban. Shan nicotinamide riboside (NR) na tsawon shekaru biyar ya rage hanzarin tsufa a agogunan PCHannum, MEAT, da DunedinPACE, yayin da horon HIIT na makonni 4‑6 ya ƙara hanzarin tsufa a DunedinPACE. Mitochondria na iya zama mahadi tsakanin su, domin canje‑canjen yawan mitochondria a tsoka suna da alaƙa da canje‑canjen MEAT‑derived EAA. A cikin wannan rubutu za mu fayyace abin da binciken ya nuna, abin da ba ya nuna, da yadda za a fassara sakamakon ba tare da yin gaggawa ba.
CoQ10 na ƙaruwa a jini, amma ba ya kai ga mitochondria
Wani sabon gwajin kan mutane ya duba tasirin karfafa ƙara CoQ10 a kan tsawon rai. A cikin manya 40 masu lafiya, masu shekaru a ƙasa da 80, shan 400 mg na CoQ10 a kowace rana na tsawon makonni 12 ya haɓaka matakin CoQ10 a jini, amma ba a samu wani canji a matakin CoQ10 a tsoka, a aikin mitochondria, ko a sarrafa sukari da VO₂max ba. Gwajin ya kasance ƙarami, gajere, kuma an yi shi ne a kan manya masu ƙarfi, yayin da babban marubuci ke bayar da shawara ga kamfanin Pharma Nord. Ga abin da sakamakon ke nuni da shi, abin da ba a iya faɗi ba, da kuma tambayoyin da har yanzu ke buƙatar amsa daga likita.
NMN Na Rage Raɗaɗin Tsoka Bayan Horaswa—Amma Da Wane Kudin?
NMN ana sayar da shi a matsayin ƙara kuzarin sel, amma sabon binciken biopsi na tsoka ya nuna wasu canje‑canje masu ban mamaki. Bayan motsa jiki mai ƙarfi da takaitaccen jini, 1,200 mg/ranun NMN ya rage siginar kumburi kamar TNF‑α da IL‑10, ya jinkirta alamar da ke da alaƙa da gyara, kuma ya hana ƙaruwar mitochondria da aka ga a ƙungiyar placebo. Binciken ya ƙunshi ƙananan maza 11 marasa horo, don haka ba zai iya zama wakili ba, amma yana kalubalantar zato na cewa rage kumburi bayan motsa jiki koyaushe yafi alheri.
Urolithin A Bai Gyara Jijiya a Makon Hudu ba, Amma Kwakwalwa Ta Amsa
Binciken da ya ƙunshi manya 50 masu shekaru 40‑64 masu kiba ya nuna cewa shan 1,000 mg na urolithin A a kowace rana tsawon makonni huɗu ba ya haɓaka faɗuwar jijiyar brachial (FMD) ko kuma canza aikin microvascular a ƙasa. Sai dai amsar hawan jini a kwakwalwa yayin aiki tana da ƙarfi sosai a ƙungiyar da ta samu urolithin A idan aka kwatanta da placebo, duk da cewa aikin kwakwalwa ba ya ƙaruwa. Wannan sakamako na biyu yana nuni da wata alamar abin sha'awa, amma ba ya ba da hujjar ƙarshe kan amfanin kari. Anan za mu kawo abin da binciken ya nuna, abin da ya rage a bayyane, da kuma abin da ke nufin ga masu tunanin ɗaukar wannan ƙari.
PQQ Ya Kara Hangen Daga Cikin Mako 12 Ga Matasa da Manyan Mutane
Wani gwaji da aka yi a boye ba tare da sanin ƙwararrun ba ya nuna cewa shan 20 mg na gishirin PQQ a kowace rana na iya inganta maki na ƙwaƙwalwa a makonni 12 ga manya masu shekaru 20‑65. Matasa sun fara ganin saurin tunani da sassauci a mako na 8, yayin da manya suka samu ƙaruwa a ƙwaƙwalwar magana da haɗe‑haɗe a mako na 12. Masu rubutun suna aiki a kamfanin da ke samar da PQQ, kuma takardar ba ta bayyana adadin mahalarta ba. Anan za mu duba abin da binciken ya nuna, abin da ba a bayyana ba, da yadda za a karanta sakamakon kafin a saya kowane samfur.
Allura ɗaya Ta mayar da mitochondria a tsokokin kunkuru tsofaffi su yi aiki kamar na matasa a cikin sa’a guda
Allura guda ɗaya na SS‑31 (elamipretide) ta mayar da samar da makamashi na mitochondria a tsokokin kunkuru tsofaffi zuwa matakin matasa cikin sa’a ɗaya. Sakamakon ya fito ne daga gwajin beraye a shekarar 2013, ba daga gwaje‑gwajen mutane ba. Peptide ɗin ba ta yi tasiri a kan tsokokin matasa ba, kuma magani na tsawon kwanaki takwas ya ƙara ƙarfin juriya a dabbobin tsofaffi. A mutane, elamipretide ta samu amincewar gaggawa daga FDA don cutar Barth, amma ta kasa cimma manyan manufofinta a gwajin MMPOWER‑3 na cutar mitochondrial myopathy. Ga abin da binciken ya nuna, ƙalubalen da ke gabatarwa, da kuma dalilin da ya sa samfuran da ba su da izini ba su da amfani.